HK1203942A1 - Therapeutically active compounds and their methods of use - Google Patents

Therapeutically active compounds and their methods of use

Info

Publication number
HK1203942A1
HK1203942A1 HK15104396.5A HK15104396A HK1203942A1 HK 1203942 A1 HK1203942 A1 HK 1203942A1 HK 15104396 A HK15104396 A HK 15104396A HK 1203942 A1 HK1203942 A1 HK 1203942A1
Authority
HK
Hong Kong
Prior art keywords
methods
active compounds
therapeutically active
therapeutically
compounds
Prior art date
Application number
HK15104396.5A
Other languages
Chinese (zh)
Inventor
.柴徹塔
.德拉巴雷
.泊泊威次-馬勒
.薩利圖如
.撒德斯
.特維斯
顏順启
郭濤
張麗
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48744984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1203942(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of HK1203942A1 publication Critical patent/HK1203942A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15104396.5A 2012-01-06 2015-05-08 Therapeutically active compounds and their methods of use HK1203942A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261584214P 2012-01-06 2012-01-06
PCT/CN2013/000009 WO2013102431A1 (en) 2012-01-06 2013-01-05 Therapeutically active compounds and their methods of use

Publications (1)

Publication Number Publication Date
HK1203942A1 true HK1203942A1 (en) 2015-11-06

Family

ID=48744984

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104396.5A HK1203942A1 (en) 2012-01-06 2015-05-08 Therapeutically active compounds and their methods of use

Country Status (39)

Country Link
US (7) US9732062B2 (en)
EP (3) EP2800743B1 (en)
JP (2) JP6411895B2 (en)
KR (1) KR101893112B1 (en)
CN (6) CN108912066B (en)
AR (1) AR090411A1 (en)
AU (2) AU2013207289B2 (en)
BR (1) BR112014016805B1 (en)
CA (1) CA2860623A1 (en)
CL (1) CL2014001793A1 (en)
CO (1) CO7030962A2 (en)
CR (1) CR20140377A (en)
CY (1) CY1120506T1 (en)
DK (1) DK2800743T3 (en)
EA (1) EA030187B1 (en)
EC (1) ECSP14012726A (en)
ES (2) ES2901430T3 (en)
HK (1) HK1203942A1 (en)
HR (1) HRP20180844T1 (en)
HU (1) HUE038403T2 (en)
IL (1) IL233503B (en)
LT (1) LT2800743T (en)
MX (1) MX358940B (en)
MY (1) MY185206A (en)
NI (1) NI201400073A (en)
NO (1) NO2897546T3 (en)
NZ (2) NZ627096A (en)
PE (1) PE20142098A1 (en)
PH (1) PH12014501561A1 (en)
PL (1) PL2800743T3 (en)
PT (1) PT2800743T (en)
RS (1) RS57401B1 (en)
SG (2) SG10201602862RA (en)
SI (1) SI2800743T1 (en)
TR (1) TR201809228T4 (en)
TW (1) TWI653228B (en)
UA (1) UA117451C2 (en)
WO (1) WO2013102431A1 (en)
ZA (1) ZA201405163B (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2755394C (en) 2009-03-13 2021-10-19 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
NZ622505A (en) 2009-06-29 2015-12-24 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
EP3561077B1 (en) 2009-10-21 2022-12-21 Les Laboratoires Servier Methods for cell-proliferation-related disorders
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
CA3088328A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
CN102827073A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Therapeutically active compositions and application methods thereof
CN102827170A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Active treatment compositions and use method thereof
AU2013207289B2 (en) 2012-01-06 2017-09-21 Les Laboratoires Servier Therapeutically active compounds and their methods of use
CA2862417C (en) 2012-01-06 2017-09-05 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
CA2888360A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105473560B (en) * 2013-07-11 2020-01-17 安吉奥斯医药品有限公司 Therapeutically active compounds and methods of use thereof
CA2917592A1 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
EP3019480B1 (en) * 2013-07-11 2020-05-06 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
TWI666208B (en) * 2013-08-02 2019-07-21 美商阿吉斯藥品有限公司 Therapeutically active compounds and their methods of use
KR102316886B1 (en) * 2013-08-02 2021-10-19 아지오스 파마슈티컬스 아이엔씨. Therapeutically active compounds and their methods of use
WO2015018060A1 (en) * 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
TWI651310B (en) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 Triterpenoids and their medical use
EP3116492A4 (en) 2014-03-14 2017-11-08 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
EP3116491B1 (en) * 2014-03-14 2021-05-05 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
WO2015144881A1 (en) * 2014-03-28 2015-10-01 Basf Se Diaminotriazine derivatives as herbicides
EP2930174A1 (en) * 2014-04-07 2015-10-14 Basf Se Diaminotriazine derivatives as herbicides
WO2015155129A1 (en) * 2014-04-07 2015-10-15 Basf Se Diaminotriazine compound
CA2961807A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016044781A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
CA2961811C (en) * 2014-09-19 2021-11-02 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
EP4257131A3 (en) 2014-09-19 2024-01-10 Forma Therapeutics, Inc. Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
AU2015324158A1 (en) * 2014-09-29 2017-04-13 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016126798A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2979537C (en) 2015-03-18 2023-08-29 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
EA038574B1 (en) * 2015-04-21 2021-09-16 Форма Терапьютикс, Инк. Pyridin-2(1h)-one quinolinone derivatives and pharmaceutical compositions thereof
WO2016171756A1 (en) * 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
WO2016177347A1 (en) * 2015-05-07 2016-11-10 Teligene Ltd Heterocyclic compounds as idh2 inhibitors
JP2018515460A (en) 2015-05-11 2018-06-14 アビデ セラピューティクス,インク. Methods for treating inflammation or neuropathic pain
HUE063541T2 (en) 2015-06-11 2024-01-28 Agios Pharmaceuticals Inc Methods of using pyruvate kinase activators
KR102303011B1 (en) * 2015-07-30 2021-09-16 치아타이 티안큉 파마수티컬 그룹 주식회사 1,3,5-triazine derivatives and methods of use thereof
EP3331866B1 (en) * 2015-08-05 2023-07-26 Les Laboratoires Servier Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine
KR102701893B1 (en) 2015-10-15 2024-09-03 셀진 코포레이션 Combination therapy for treating malignant tumors
EP3362065B1 (en) 2015-10-15 2024-04-03 Les Laboratoires Servier Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia
BR112018007304A2 (en) 2015-10-15 2018-10-23 Agios Pharmaceuticals Inc Combination therapy for treatment of malignancies
MX2018004586A (en) 2015-10-15 2018-08-16 Agios Pharmaceuticals Inc Combination therapy for treating malignancies.
MA43848A (en) * 2015-10-21 2018-11-21 Neuform Pharmaceuticals Inc DEUTERATED COMPOUNDS FOR THE TREATMENT OF MALIGNANT HEMOPATHIES, ASSOCIATED COMPOSITIONS AND PROCEDURES
IL299563A (en) 2015-12-04 2023-02-01 Agios Pharmaceuticals Inc Methods of treatment of acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
CN105503754B (en) * 2015-12-11 2017-11-17 浙江大学 The triazine of 2 amino, 4 benzyl, 6 morpholine 1,3,5 and its preparation and application
CN105384702B (en) * 2015-12-11 2018-04-10 浙江大学 Three substitution s-triazine compounds and preparation method thereof
CN105399695B (en) * 2015-12-11 2019-04-19 浙江大学 Compound in triazine class and its preparation method and application
WO2017140758A1 (en) 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
EP3419593B1 (en) 2016-02-26 2022-03-23 Celgene Corporation Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia
CN105753801B (en) * 2016-03-25 2018-06-01 浙江工业大学 preparation method of s-triazine compound
CN105820133B (en) * 2016-03-25 2018-06-05 浙江工业大学 Polysubstituted s-triazine compound and preparation method and application thereof
CA3029343C (en) * 2016-07-21 2021-02-09 Nanjing Sanhome Pharmaceutical Co., Ltd. Chemical compound of isocitrate dehydrogenase inhibitor, and application thereof
US20180042930A1 (en) * 2016-08-03 2018-02-15 Celgene Corporation Methods of treatment of malignancies
SG11201901873PA (en) 2016-09-07 2019-03-28 Celgene Corp Tablet compositions
WO2018053447A1 (en) 2016-09-19 2018-03-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
JOP20190106A1 (en) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc Magl inhibitors
JOP20190105A1 (en) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc Magl inhibitors
ES2924500T3 (en) * 2017-01-22 2022-10-07 Chia Tai Tianqing Pharmaceutical Group Co Ltd 1,3,5-triazine derivative salt, crystal, preparation method, pharmaceutical composition and use thereof
JP2020518629A (en) * 2017-05-05 2020-06-25 メモリアル スローン ケタリング キャンサー センター How to treat myeloproliferative tumors
SG11201913008TA (en) 2017-06-30 2020-01-30 Celgene Corp Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-doxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
CN109265444B (en) * 2017-07-17 2022-03-11 南京圣和药业股份有限公司 Optical isomer of substituted triazine IDH inhibitor and application thereof
CN109467538A (en) 2017-09-07 2019-03-15 和记黄埔医药(上海)有限公司 The heteroaryl cyclics and application thereof that cycloolefin replaces
CN110054615B (en) * 2018-01-19 2021-06-15 南京圣和药业股份有限公司 Crystal form of triazine IDH inhibitor mesylate
CN110054617A (en) * 2018-01-19 2019-07-26 南京圣和药业股份有限公司 Compound in triazine class, preparation method and the usage
CN110051673B (en) * 2018-01-19 2022-03-11 南京圣和药业股份有限公司 Pharmaceutical composition containing triazine IDH inhibitor and application thereof
CN110054616B (en) * 2018-01-19 2021-11-23 南京圣和药业股份有限公司 Preparation method of triazine IDH inhibitor
AU2019271123A1 (en) 2018-05-15 2020-11-26 H. Lundbeck A/S. MAGL inhibitors
PT3720442T (en) 2018-05-16 2023-03-13 Forma Therapeutics Inc Inhibiting mutant idh-1
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US10532047B2 (en) 2018-05-16 2020-01-14 Forma Therapeutics, Inc. Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
KR102328682B1 (en) * 2018-08-27 2021-11-18 주식회사 대웅제약 Novel heterocyclicamine derivatives and pharmaceutical composition comprising the same
WO2020092915A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Solid dispersions for treatment of cancer
US20220017490A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
US20210403452A1 (en) 2018-11-02 2021-12-30 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
CN111662275B (en) * 2019-03-08 2023-08-22 中国药科大学 Benzenesulfonamide IDH mutant inhibitor, preparation method and application thereof
CN111662271B (en) * 2019-03-08 2023-11-14 中国药科大学 Compound with IDH mutant inhibitory activity and preparation method and application thereof
WO2020239759A1 (en) 2019-05-27 2020-12-03 Sandoz Ag Amorphous enasidenib in a stabilized form
CN114502537A (en) * 2019-09-29 2022-05-13 贝达药业股份有限公司 Mutant IDH2 inhibitor and application thereof
EP4058028A1 (en) 2019-11-14 2022-09-21 Celgene Corporation Pediatric formulations for treatment of cancer
BR112021025516A2 (en) 2020-04-21 2022-11-01 H Lundbeck As PROCESSES FOR MANUFACTURING 1,1,1,3,3,3-HEXAFLUOROPROPAN-2-ILA 4-(2-(PYRROLIDIN-1-IL)-4-(TRIFLUOROMETHYL)BENZYL)PIPERAZINE-1-CARBOXYLATE AND SAME MONOCHLORIDATE SALT FORM 2
CN111592524B (en) * 2020-05-20 2023-11-17 温州市天聚万迅信息科技有限公司 Preparation method of Enxidani
WO2022074587A1 (en) * 2020-10-06 2022-04-14 Kures, Inc. Mu-opioid receptor agonists and uses therefor
AU2022219973A1 (en) * 2021-02-12 2023-09-07 Les Laboratoires Servier Therapeutically active compounds and their methods of use
US11865079B2 (en) 2021-02-12 2024-01-09 Servier Pharmaceuticals Llc Therapeutically active compounds and their methods of use
CN113461660B (en) * 2021-06-11 2022-08-02 浙江大学 2,4, 6-trisubstituted-1, 3, 5-s-triazine compound, preparation and application thereof
WO2023174235A1 (en) * 2022-03-15 2023-09-21 贝达药业股份有限公司 Mutant idh1 and idh2 inhibitor and application thereof
TW202400575A (en) 2022-03-24 2024-01-01 美商A2A製藥公司 Compositions and methods for treating cancer
CN114773320A (en) * 2022-05-29 2022-07-22 重庆医科大学 1,3,5-triazine compound, preparation method and application thereof
CN115536637A (en) * 2022-10-24 2022-12-30 陕西中医药大学 S-triazine derivative and its synthesis method and use

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
BE754242A (en) 1970-07-15 1971-02-01 Geigy Ag J R DIAMINO-S-TRIAZINES AND DINITRO-S-TRIAZINES
US3867383A (en) 1971-03-29 1975-02-18 Ciba Geigy Corp Monoanthranilatoanilino-s-triazines
CH606334A5 (en) 1974-06-21 1978-10-31 Ciba Geigy Ag
JPS58186682A (en) 1982-04-27 1983-10-31 日本化薬株式会社 Dyeing of cellulose or cellulose containing fiber material
DE3512630A1 (en) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt METHOD FOR COLORING OR PRINTING CELLULOSE FIBERS OR CELLULOSE MIXED FIBERS
US5041443A (en) 1989-02-21 1991-08-20 Dainippon Pharmaceutical Co., Ltd. Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof
DK0385237T3 (en) 1989-03-03 1994-07-25 Dainippon Pharmaceutical Co 2- (1-Piperazinyl) -4-phenylcycloalkanopyridine derivatives, process for their preparation and pharmaceutical composition containing them
ATE130882T1 (en) 1990-07-12 1995-12-15 Ciba Geigy Ag METHOD FOR THE PHOTOCHEMICAL AND THERMAL STABILIZATION OF POLYAMIDE FIBER MATERIALS.
JPH0499768A (en) 1990-08-17 1992-03-31 Dainippon Pharmaceut Co Ltd 4-(4-phenylpyridin-2-yl)piperazine-1-oxide derivative
EP0629622B1 (en) 1992-02-28 1998-11-11 Zenyaku Kogyo Kabushikikaisha S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
FR2735127B1 (en) 1995-06-09 1997-08-22 Pf Medicament NEW HETEROAROMATIC PIPERAZINES USEFUL AS MEDICAMENTS.
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
JPH09291034A (en) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd Condensed pyridine compound and its use as medicine
WO1997044322A1 (en) 1996-05-20 1997-11-27 Darwin Discovery Limited Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
US5984882A (en) 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
EP0945446A4 (en) 1996-11-14 1999-12-08 Nissan Chemical Ind Ltd Cyanoethylmelamine derivatives and process for producing the same
US6399358B1 (en) 1997-03-31 2002-06-04 Thomas Jefferson University Human gene encoding human chondroitin 6-sulfotransferase
JPH11158073A (en) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd Adenosine a3 antagonist
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
UY25842A1 (en) 1998-12-16 2001-04-30 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US6274620B1 (en) 1999-06-07 2001-08-14 Biochem Pharma Inc. Thiophene integrin inhibitors
DE60023920T2 (en) 1999-08-27 2006-07-20 Sugen, Inc., South San Francisco Phosphate mimetics and methods of treatment with phosphatase inhibitors HIBITORS
WO2002002313A1 (en) 2000-07-03 2002-01-10 Kansai Paint Co., Ltd. Gas-barrier film
KR20030024799A (en) 2000-07-20 2003-03-26 뉴로젠 코포레이션 Capsaicin receptor ligands
JP2005500294A (en) 2001-06-19 2005-01-06 ブリストル−マイヤーズ スクイブ カンパニー Pyrimidine inhibitors for phosphodiesterase 7
WO2003016289A1 (en) 2001-08-17 2003-02-27 Ciba Specialty Chemicals Holding Inc. Triazine derivatives and their use as sunscreens
JP4753336B2 (en) 2001-09-04 2011-08-24 日本化薬株式会社 Novel allyl compound and process for producing the same
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
US6878196B2 (en) 2002-01-15 2005-04-12 Fuji Photo Film Co., Ltd. Ink, ink jet recording method and azo compound
US20040067234A1 (en) 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
US7205298B2 (en) 2002-07-18 2007-04-17 Janssen Pharmaceutica N.V. Substituted triazine kinase inhibitors
JP2004107220A (en) 2002-09-13 2004-04-08 Mitsubishi Pharma Corp TNF-alpha PRODUCTION INHIBITOR
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
WO2004050033A2 (en) 2002-12-02 2004-06-17 Arqule, Inc. Method of treating cancers
CA2510087C (en) 2002-12-16 2018-09-04 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (il-8)
WO2004062604A2 (en) 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2004073619A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
WO2004074438A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
US7582645B2 (en) 2003-10-10 2009-09-01 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders
AU2003297904A1 (en) 2003-12-12 2005-07-14 University Of Maryland, Baltimore Immunomodulatory compounds that target and inhibit the py+3 binding site of tyrosene kinase p56 lck sh2 domain
KR20070007055A (en) 2003-12-24 2007-01-12 사이오스 인코퍼레이티드 Treatment of malignant gliomas with tgf-beta inhibitors
EP1805142A4 (en) 2004-09-23 2009-06-10 Reddy Us Therapeutics Inc Novel pyridine compounds, process for their preparation and compositions containing them
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
BRPI0606930A2 (en) 2005-01-25 2009-12-01 Astrazeneca Ab compound or a pharmaceutically acceptable salt thereof, process for preparing a compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, and methods for producing a drug inhibiting effect. b-raf in a warm-blooded animal, for producing an anti-cancer effect on a warm-blooded animal and for treating diseases of an animal in a warm-blooded animal
US8278038B2 (en) 2005-06-08 2012-10-02 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
US8071597B2 (en) 2005-08-26 2011-12-06 Merck Serono Sa Pyrazine compounds and uses as PI3K inhibitors
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
TW200815426A (en) 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
EP2121662A1 (en) 2006-12-04 2009-11-25 Neurocrine Biosciences, Inc. Substituted pyrimidines as adenosine receptor antagonists
JP5622393B2 (en) 2006-12-15 2014-11-12 アブラクシスバイオサイエンス リミテッド ライアビリティー カンパニー Triazine derivatives and their therapeutic applications
EP2152676B1 (en) * 2007-04-30 2013-04-03 ProMetic BioSciences Inc. "triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives"
JP2010529193A (en) 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド Substituted pyrazole compounds
BRPI0814628B1 (en) 2007-07-20 2022-04-05 Nerviano Medical Sciences S.R.L. Active substituted indazole derivatives as kinase inhibitors
WO2009027736A2 (en) * 2007-08-27 2009-03-05 Astrazeneca Ab 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
US20100234389A1 (en) 2007-10-10 2010-09-16 Takeda Pharmaceutical Company Limited Amide compound
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
JP5277685B2 (en) 2008-03-26 2013-08-28 富士ゼロックス株式会社 Electrophotographic photosensitive member, image forming apparatus, process cartridge, and image forming method
CN101575408B (en) 2008-05-09 2013-10-30 Mca技术有限公司 Polytriazinyl compounds as flame retardants and light stabilizers
FR2932483A1 (en) 2008-06-13 2009-12-18 Cytomics Systems COMPOUNDS USEFUL FOR THE TREATMENT OF CANCERS.
WO2010007756A1 (en) 2008-07-14 2010-01-21 塩野義製薬株式会社 Pyridine derivative having ttk inhibition activity
US20100144722A1 (en) 2008-09-03 2010-06-10 Dr. Reddy's Laboratories Ltd. Novel heterocyclic compounds as gata modulators
MX359574B (en) 2008-09-03 2018-10-03 Univ Johns Hopkins GENETIC ALTERATIONS IN ISOCITRATE DEHYDROGENASE and OTHER GENES IN MALIGNANT GLIOMA.
JP2010079130A (en) 2008-09-29 2010-04-08 Fuji Xerox Co Ltd Electrophotographic photoreceptor, process cartridge, and image forming apparatus
JP2010181540A (en) 2009-02-04 2010-08-19 Fuji Xerox Co Ltd Electrophotographic photoreceptor, process cartridge and image forming apparatus
DK2394999T3 (en) * 2009-02-06 2014-05-05 Nippon Shinyaku Co Ltd AMINOPYRAZINE DERIVATIVE AND MEDICINE
CA2755394C (en) 2009-03-13 2021-10-19 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
AU2010259002B2 (en) 2009-06-08 2014-03-20 Nantbio, Inc. Triazine derivatives and their therapeutical applications
US8261872B2 (en) 2009-06-08 2012-09-11 Clark Equipment Company Work machine having modular ignition switch keypad with latching output
WO2010144404A1 (en) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Pyridil-triazine inhibitors of hedgehog signaling
WO2010144522A1 (en) 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Ureidophenyl substituted triazine derivatives and their therapeutical applications
WO2011005208A1 (en) 2009-07-10 2011-01-13 Milux Holding S.A. Knee joint device and method
JP5473851B2 (en) 2009-09-30 2014-04-16 富士フイルム株式会社 Polymer film, retardation film, polarizing plate and liquid crystal display device
EP3561077B1 (en) 2009-10-21 2022-12-21 Les Laboratoires Servier Methods for cell-proliferation-related disorders
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
JP5967827B2 (en) 2009-12-09 2016-08-10 アジオス ファーマシューティカルズ, インコーポレイテッド Therapeutically active compounds for the treatment of cancer characterized by having an IDH variant
US20130197106A1 (en) 2010-04-01 2013-08-01 Agios Pharmaceuticals, Inc Methods of identifying a candidate compound
ES2704862T3 (en) 2010-07-16 2019-03-20 Agios Pharmaceuticals Inc Therapeutically active compositions and their method of use
JP5907986B2 (en) 2010-11-29 2016-04-26 ガリオン ファーマシューティカルズ インコーポレイテッド Compounds as respiratory stimulants for the treatment of respiratory control disorders or respiratory control disorders
TWI555737B (en) 2011-05-24 2016-11-01 拜耳知識產權公司 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
CN102827170A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Active treatment compositions and use method thereof
CN102827073A (en) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 Therapeutically active compositions and application methods thereof
CN102659765B (en) 2011-12-31 2014-09-10 沈阳药科大学 Pyrimidine and triazine compound preparation method and application
AU2013207289B2 (en) * 2012-01-06 2017-09-21 Les Laboratoires Servier Therapeutically active compounds and their methods of use
CA2862417C (en) 2012-01-06 2017-09-05 Abide Therapeutics, Inc. Carbamate compounds and of making and using same
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
CA2860858A1 (en) 2012-01-19 2013-07-25 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
IN2014MN01897A (en) 2012-03-09 2015-07-10 Carna Biosciences Inc
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
SG10201602862RA (en) 2016-05-30
DK2800743T3 (en) 2018-06-14
NI201400073A (en) 2014-12-22
WO2013102431A1 (en) 2013-07-11
CN115536635A (en) 2022-12-30
CY1120506T1 (en) 2019-07-10
EP3984997A1 (en) 2022-04-20
EP2800743A4 (en) 2015-08-26
US20230250078A1 (en) 2023-08-10
CN114933585A (en) 2022-08-23
SI2800743T1 (en) 2018-08-31
NZ627096A (en) 2017-02-24
AU2017265096A1 (en) 2017-12-14
PL2800743T3 (en) 2018-09-28
KR20140113712A (en) 2014-09-24
CN104114543B (en) 2019-03-15
ECSP14012726A (en) 2016-01-29
AU2013207289B2 (en) 2017-09-21
ZA201405163B (en) 2018-05-30
EP3406608B8 (en) 2022-01-19
US9512107B2 (en) 2016-12-06
BR112014016805B1 (en) 2019-07-30
BR112014016805A2 (en) 2017-06-13
IL233503A0 (en) 2014-08-31
IL233503B (en) 2018-07-31
HRP20180844T1 (en) 2018-08-24
MX2014008350A (en) 2014-10-06
US20220348554A1 (en) 2022-11-03
EP3406608A1 (en) 2018-11-28
JP2017075193A (en) 2017-04-20
KR101893112B1 (en) 2018-08-30
CN107417667A (en) 2017-12-01
TWI653228B (en) 2019-03-11
NO2897546T3 (en) 2018-01-13
NZ722582A (en) 2018-02-23
CL2014001793A1 (en) 2014-11-07
RS57401B1 (en) 2018-09-28
CN108912066B (en) 2022-06-24
CN104114543A (en) 2014-10-22
MY185206A (en) 2021-04-30
TR201809228T4 (en) 2018-07-23
LT2800743T (en) 2018-06-25
CA2860623A1 (en) 2013-07-11
ES2901430T3 (en) 2022-03-22
PE20142098A1 (en) 2015-01-08
US20200079755A1 (en) 2020-03-12
AU2017265096B9 (en) 2019-09-05
TW201329054A (en) 2013-07-16
US20130190287A1 (en) 2013-07-25
PT2800743T (en) 2018-07-04
US9732062B2 (en) 2017-08-15
US20170298045A1 (en) 2017-10-19
US20170044139A1 (en) 2017-02-16
JP6409081B2 (en) 2018-10-17
EA030187B1 (en) 2018-07-31
CN107417667B (en) 2020-04-10
AU2013207289A2 (en) 2014-07-31
PH12014501561B1 (en) 2014-10-08
EP2800743B1 (en) 2018-04-04
US9656999B2 (en) 2017-05-23
JP6411895B2 (en) 2018-10-24
AU2013207289A1 (en) 2014-07-31
US11505538B1 (en) 2022-11-22
EP3406608B1 (en) 2021-09-15
EP2800743A1 (en) 2014-11-12
US10294215B2 (en) 2019-05-21
HUE038403T2 (en) 2018-10-29
CN108912066A (en) 2018-11-30
CR20140377A (en) 2014-11-13
JP2015503571A (en) 2015-02-02
US20160318903A1 (en) 2016-11-03
ES2675760T3 (en) 2018-07-12
PH12014501561A1 (en) 2014-10-08
EA201491330A1 (en) 2015-04-30
BR112014016805A8 (en) 2017-07-04
AR090411A1 (en) 2014-11-12
SG11201403878QA (en) 2014-08-28
AU2017265096B2 (en) 2019-08-08
MX358940B (en) 2018-09-10
CO7030962A2 (en) 2014-08-21
UA117451C2 (en) 2018-08-10
CN115521264A (en) 2022-12-27

Similar Documents

Publication Publication Date Title
ZA202100373B (en) Therapeutically active compounds and their methods of use
IL270347B (en) Therapeutically active compounds and their methods of use
HK1203942A1 (en) Therapeutically active compounds and their methods of use
HK1204319A1 (en) Therapeutically active compounds and their methods of use
HRP20181628T1 (en) Compounds and their methods of use
HK1217948A1 (en) Therapeutically active compounds and their methods of use
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
EP2721019A4 (en) Therapeutically active compositions and their methods of use
HK1223924A1 (en) Therapeutically active compounds and their methods of use
ZA201408128B (en) Etract of greyia radlkoferi and use thereof